Morgan Stanley Sqz Biotechnologies CO Transaction History

Morgan Stanley

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.27 - $0.68 $76,302 - $192,168	-282,601 Reduced 94.28%	17,135 $4,000
Q1 2023 May 15, 2023	BUY	$0.53 - $0.87 $157,123 - $257,920	296,460 Added 9049.45%	299,736 $167,000
Q4 2022 Feb 14, 2023	SELL	$0.67 - $2.85 $6,797 - $28,913	-10,145 Reduced 75.59%	3,276 $2,000
Q3 2022 Nov 14, 2022	SELL	$2.16 - $3.48 $51,701 - $83,297	-23,936 Reduced 64.07%	13,421 $30,000
Q2 2022 Oct 27, 2022	BUY	$2.77 - $5.0 $48,588 - $87,705	17,541 Added 88.52%	37,357 $118,000
Q2 2022 Aug 15, 2022	BUY	$2.77 - $5.0 $48,588 - $87,705	17,541 Added 88.52%	37,357 $118,000
Q1 2022 Oct 27, 2022	SELL	$4.01 - $10.42 $70,339 - $182,777	-17,541 Reduced 46.96%	19,816 $95,000
Q1 2022 May 13, 2022	BUY	$4.01 - $10.42 $36,057 - $93,696	8,992 Added 83.07%	19,816 $95,000
Q4 2021 Feb 14, 2022	BUY	$8.93 - $14.85 $37,845 - $62,934	4,238 Added 64.35%	10,824 $96,000
Q3 2021 Nov 15, 2021	BUY	$11.46 - $15.77 $75,475 - $103,861	6,586 New	6,586 $94,000

1.47M

Ticker SQZ
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,248,600
Market Cap $1.46M
Description
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.